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Non–ischemic cardiomyopathy (NICM) is a common cause of congestive heart failure (CHF) with a preva-
lence of ≥1 in 2500 adults1 and a 5-year mortality as high 
as 20%.2 A preclinical phase may precede the development 
of CHF in patients with NICM.3–5 However, information 
on the clinical course of this condition is scarce, given that 
most of the data are focused on preclinical left ventricular 
(LV) systolic dysfunction (SD) because of ischemic heart 
disease.6–9 Population-based, cross-sectional cohort studies 
have shown that preclinical LVSD is as prevalent as CHF in 
the general population6–9 and is associated with an increased 
risk of CHF and mortality irrespective of the pathogenesis 
causing ventricular dysfunction.6,7 The identification of 
prognostic predictors in patients with preclinical LVSD is 
crucial for an effective risk stratification and surveillance 
of patients. In fact, optimization of medical therapy at this 
early stage may delay or may prevent progression to CHF,10 
lessening the social and economic burden imposed by this 
condition.
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Background—We conducted a prospective longitudinal study to investigate the yet unknown clinical significance of 
myocardial fibrosis in patients with non–ischemic cardiomyopathy without history of congestive heart failure (CHF).
Methods and Results—At 3 tertiary referral centers, 228 patients with non–ischemic cardiomyopathy without history 
of CHF were studied with cardiovascular magnetic resonance for late gadolinium enhancement (LGE) detection and 
quantification and prospectively followed up for a median of 23 months. The end point was a composite of cardiac death, 
onset of CHF, and aborted sudden cardiac death. LGE was detected in 61 (27%) patients. Thirty-one of 61 (51%) patients 
with LGE reached combined end point when compared with 18 of 167 (11%) patients without LGE (hazard ratio, 5.10 
[2.78–9.36]; P<0.001). Patients with LGE had greater risk of developing CHF than patients without LGE (hazard ratio, 
5.23 [2.61–10.50]; P<0.001) and higher rate of aborted sudden cardiac death (hazard ratio, 8.31 [1.66–41.55]; P=0.010). 
Multivariate analysis showed that LGE was associated with high likelihood of composite end point independent of other 
prognostic determinants, including age; duration of cardiomyopathy; and left ventricular volumes, mass, and ejection 
fraction (hazard ratio, 4.02 [2.08–7.76]; P<0.001). Improvement χ2 analysis disclosed that LGE addition to models, 
including clinical data alone or in combination with parameters of left ventricular remodeling and function, yielded an 
improvement in outcome prediction (P<0.001). Addition of LGE to age and left ventricular ejection fraction improved 
risk stratification for composite end point (net reclassification improvement, 29.6%) and onset of CHF (net reclassification 
improvement, 25.4%; both P<0.001).
Conclusions—In patients with non–ischemic cardiomyopathy without history of CHF, myocardial fibrosis is a strong and 
independent predictor of outcome, providing incremental prognostic information and improvement in risk stratification 
beyond clinical data and degree of left ventricular dysfunction.  (Circ Heart Fail. 2014;7:448-456.)
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In patients with NICM and history of CHF replacement 
myocardial fibrosis detected by late gadolinium enhancement 
(LGE) technique using cardiovascular magnetic resonance 
(CMR) has been shown to be a strong and an independent 
predictor of outcome.3,11–14 To date, there are no data on the 
clinical value of fibrosis in patients with NICM without his-
tory of CHF. On the basis of these premises, we performed 
a multicenter longitudinal prospective study in a cohort of 
patients with NICM without history of CHF to investigate 
the prognostic significance of myocardial fibrosis detected by 
LGE technique using contrast-enhanced CMR.
Methods
Study Design and Subjects
This is a prespecified multicenter longitudinal prospective study con-
ducted in a cohort of patients with NICM without history of CHF 
as part of a larger prospective registry of consecutive patients with 
NICM referred for CMR. Between July 2004 and December 2012, 
765 consecutive patients with NICM were evaluated at 3 referral cen-
ters (585 at Fondazione CNR-Regione Toscana ‘G.Monasterio’, Pisa, 
Italy [center A]; 105 at Gasthuisberg University Hospital, Leuven, 
Belgium [center B], and 75 at Centro Cardiologico Monzino, Milano, 
Italy [center C]) for study enrollment. The inclusion criteria were (1) 
reduced LV ejection fraction at transthoracic echocardiography based 
on published reference ranges,15 (2) absent significant coronary artery 
stenosis at invasive coronary angiography or cardiac computed tomog-
raphy,16 (3) absent history of CHF based on Framingham Criteria.6 
Before inclusion, the diagnosis of LVSD was confirmed by CMR 
on the basis of reduced LV ejection fraction when compared with 
published reference ranges normalized for age and sex.17 Exclusion 
criteria included age <18 years old, recent myocarditis, peripartum 
cardiomyopathy, arrhythmogenic right ventricular dysplasia/cardio-
myopathy, severe primary valvular disease, untreated hypertension, 
end-stage hypertrophic cardiomyopathy, cardiac amyloidosis, esti-
mated glomerular filtration rate <30 mL/min, and contraindications 
to CMR. Each subject underwent complete clinical history, physical 
examination, ECG, and CMR. Clinical and CMR data were collected 
at each center by 2 experienced physicians in charge of the study. All 
data were then anonymized and transferred to center A for analysis. 
The protocol was approved by each Institution Ethical Committee, 
and all patients gave written informed consent.
Definition of CHF
The diagnosis of CHF was based on Framingham Criteria, consisting 
in the presence of 2 major or 1 major and 2 minor clinical criteria, 
which could not be attributed to another diagnosis.6 Major criteria 
were paroxysmal nocturnal dyspnea or orthopnea, pulmonary edema, 
increased central venous pressure (distended neck veins and hepa-
tojugular reflux), rales at pulmonary auscultation, third heart sound, 
and weight loss on diuretic therapy. Minor criteria were bilateral 
ankle edema, night cough, dyspnea on exertion, pleural effusion and 
pulmonary vascular redistribution, tachycardia, and hepatomegaly 
and decreased in vital capacity.
CMR Protocol
CMR studies were performed at center A with 1.5-T unit (CVi; 
 GE-Healthcare, Milwaukee, WI), at center B with 1.5-T unit 
 (Intera-CV; Philips, Best, The Netherlands), and at center C with 1.5-T 
unit (Discovery MR450; GE-Healthcare). All studies were performed 
using dedicated cardiac software, phased-array surface receiver coil, 
and ECG triggering. A similar CMR study protocol was followed in 
all centers (see Data Supplement). In brief, cine images in horizon-
tal, vertical, and short-axis views were acquired using  breath-hold 
cine steady-state free-precession sequence. For the quantification of 
LV volumes, stroke volume, ejection fraction, and mass, cine images 
were acquired in a stack of contiguous short-axis slices from base to 
apex. Postcontrast breath-hold T1-weighted  2-dimensional (2D; CVi; 
GE Healthcare/Discovery MR450; GE-Healthcare) or 3D  (Intera-CV; 
Philips) inversion-recovery segmented gradient-echo sequence was 
used for detection and quantification of LGE. Ten to 20 minutes after 
intravenous bolus of 0.1 mmol/kg of gadolinium-gadobenate dimeglu-
mine (Multihance; Bracco, Milan, Italy; center C) or 0.2 mmol/kg 
gadolinium-tetraazacyclododecane-tetraacetic acid (Dotarem, Guerbet, 
France; centers A and B), LGE images were acquired using the same 
views used for cine images. The inversion time was individually adapt-
ed to suppress the signal of normal myocardium (220–350 ms).
Image Analysis
All CMR studies were centrally analyzed in center A using a worksta-
tion (Advantage; GE-Healthcare) with a dedicated software (MASS 
6.1; Medis, Leiden, Netherlands). The analysis started with postcon-
trast images. The presence of LGE was assigned by the consensus of 
2 experienced operators (A.D.T. and A.B.) blinded to clinical data. 
Myocardial LGE was considered present if the hyperenhanced myo-
cardium was confined to midwall or subepicardial layers detectable in 
2 perpendicular views.13 A third operator (P.G.M.) blinded to clinical 
data adjudicated the presence or absence of LGE in case of disagree-
ment (n=3). When present, LGE was semiquantitatively graded by an 
operator (A.B.). LV was segmented based on 17-segment model ac-
cording to American Heart Association recommendation,18 segment 
17 was excluded from further analysis. Using short-axis stack of LGE 
images, a segment was considered involved when the hyperintense 
myocardium occupied >50% of its circumferential extent. Sum of 
segments showing LGE was used as a semiquantitative score of LGE 
extent. LV volumes, stroke volume, mass, and ejection fraction were 
quantified using the stack of cine short-axis images. LV volumes, 
stroke volume, and mass were normalized to body surface area.
Clinical Follow-Up and End Points
Follow-up was performed till July 2013. All events were centrally 
adjudicated at center A by the consensus of 2 experienced cardiolo-
gists blinded to CMR results (M.E. and M.L.). At 6- to 12-month in-
tervals, all patients were followed up for nonfatal event by telephone 
interview, review of outpatient clinics or hospitalization records, and 
contact with primary care physician or cardiologists of patients. After 
hospitalization, medical records were reviewed to define the cause 
of admission. The cause of death was defined from a combination 
of death certification, postmortem data (when available), medical re-
cords, and communication with primary care physician or cardiolo-
gist of patients. Type of death was classified according to a modified 
Hinkle–Thaler system.19 Patients who died of noncardiac causes were 
considered censored at the time of the event. Sudden cardiac death 
(SCD) was defined as unexpected death either within 1 hour of cardiac 
symptoms in the absence of progressive deterioration and during sleep 
or within 24 hours of last being seen alive. Aborted SCD was diag-
nosed in patients who received an appropriate implantable cardiovert-
er-defibrillator (ICD) intervention for ventricular arrhythmia or had a 
nonfatal episode of ventricular fibrillation or spontaneous sustained 
ventricular tachycardia (>30 s in duration), causing hemodynamic 
compromise and requiring cardioversion. CHF death was defined as 
death associated with unstable, progressive deterioration of pump 
function, despite active therapy. Onset of CHF was defined according 
to Framingham Criteria as indicated above. The predefined end point 
was a composite of cardiac death, onset of CHF, and aborted SCD.
Statistical Analysis
Continuous variables were expressed as mean±SD or median and 25th 
to 75th percentiles and categorical variables as frequency with percent-
age. Student independent t or Mann–Whitney tests were used as ap-
propriate to compare continuous variables between patients with and 
without LGE. Comparisons between groups on categorical variables 
were performed by χ2 or by Fisher exact test if the expected cell count 
was <5. Survival curves were obtained by Kaplan–Meier analysis and 
compared by log-rank test. The time to events was calculated from the 
CMR date. Univariate Cox proportional hazard models were used to 
 at KU Leuven University Library on September 22, 2014http://circheartfailure.ahajournals.org/Downloaded from 
450  Circ Heart Fail  May 2014
assess the association between baseline covariates and composite end 
point (results presented as hazard ratio and 95% confidence interval). 
Variables with P<0.10 at univariate analysis were then included as co-
variates in multivariate Cox proportional hazard models to test which 
variables were independently associated with the composite end point. 
Considering the strong correlation between LV ejection fraction and 
LV end-systolic volume index (Pearson correlation coefficient, r=–
0.811; P<0.001), LV ejection fraction (model 1) and LV end-systolic 
volume index (model 2) were introduced separately in the multivariate 
analysis. The presence and extent of LGE were introduced separately 
in both model 1 (LGE presence in model 1a and LGE extent in model 
1b) and model 2 (LGE presence in model 2a and LGE extent model 
2b). For each model, the incremental value in predicting composite 
end point by stepwise inclusion of CMR parameters of LV remodeling 
and function (LV volumes, mass, and ejection fraction) and fibrosis 
(presence or extent of LGE) in addition to clinical data (age and dura-
tion of cardiomyopathy) was assessed by the χ2 using Omnibus test of 
model coefficients. For each model, goodness-of-fit statistics were ob-
tained by means of log likelihood and Akaike Information Criterion, 
as well as Bayesian Information Criterion. Reclassification of patients 
was determined using net reclassification improvement analysis for 
combined end point and onset of CHF. For each end point, the net 
reclassification improvement and risk reclassification tables were used 
to determine reclassification of patients obtained by adding LGE sta-
tus to the model based on age and LV ejection fraction.20 Because no 
conventional cutoff values exist for composite end point and onset of 
CHF in such population, risk categories were determined on the basis 
of mean event rate at 2 years of follow-up. For composite end point, a 
threshold of 15% was used to stratify patients in low-risk (<15%) and 
high-risk (≥15%) categories. For onset of CHF, a threshold of 10% 
Figure 1. Study protocol. CHF indicates congestive heart failure; 
CMR, cardiovascular magnetic resonance; LV, left ventricular; 
and NICM, non–ischemic cardiomyopathy.
Table 1. Baseline Characteristics in Whole Study Population and in Patients With and Without LGE
Variables All (n=228) Patients With LGE (n=61) Patients Without LGE (n=167) P Value
Age, y 50±15 50±15 50±15 0.868
Women, n (%) 47 (21) 10 (16) 37 (22) 0.341
BMI, kg/m2 26±4 26±3 25±4 0.599
Duration of CM, mo 7 (1–48) 9 (2–73) 6 (1–43) 0.178
Family history of CM 51 (22) 15 (25) 36 (22) 0.627
Hypertension, n (%) 67 (29) 15 (25) 52 (31) 0.324
Diabetes mellitus, n (%) 20 (9) 7 (11) 13 (8) 0.383
Smoking, n (%) 88 (39) 22 (36) 66 (39) 0.635
Dyslipidemia, n (%) 58 (25) 18 (30) 40 (24) 0.394
Alcohol abuse 15 (7) 4 (7) 11 (7) 0.991
Hemoglobin, g/dL 13±1 13±1 13±2 0.876
Creatinine, mg/dL 0.90±0.20 0.95±0.20 0.92±0.21 0.439
Atrial fibrillation, n (%) 16 (7) 5 (8) 11 (7) 0.674
LBBB, n (%) 56 (25) 13 (21) 43 (26) 0.491
QRS duration, ms 120±27 122±26 120±27 0.750
CMR data
  LGE, n (%) 61 (27) … … …
  LGE no. of segments 0 (0–1) 3 (2–6) … …
  LVEDVi, mL/m2 115±31 117±28 115±32 0.674
  LVESVi, mL/m2 68±30 68±26 68±31 0.905
  LVMi, g/m2 83±23 88±26 82±22 0.061
  LVSVi, mL/m2 48±10 49±11 47±9 0.360
  LVEF, % 43±10 43±10 43±10 0.925
  LVEF<35%, n (%) 52 (23) 14 (23) 38 (23) 0.975
Medications
  ACEi/ARBs, n (%) 201 (88) 51 (84) 150 (89) 0.456
  β-Blockers, n (%) 187 (82) 50 (82) 145 (87) 0.495
  Spironolactone, n (%) 56 (25) 15 (24) 41 (25) 0.911
ACEi indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin-II inhibitor; BMI, body mass index; CM, cardiomyopathy; CMR, 
cardiovascular magnetic resonance; EDVi, end-diastolic volume index; EF, ejection fraction; ESVi, end-systolic volume index; LBBB, left bundle 
branch block; LGE, late gadolinium enhancement; LV, left ventricular; Mi, mass index; and SVi, stroke volume index.
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was used to stratify patients in low-risk (<10%) and high-risk (≥10%) 
categories. All tests were 2-tailed, and P<0.05 was considered statis-
tically significant. Analyses were performed using SSPS version 15 
(SPSS, Chicago, IL) and R-statistic 2.15.
Results
Study Population
Overall 228 patients met the enrollment criteria, and no 
patients were lost to follow-up (Figure 1). Of the whole popu-
lation, 151 patients complained with a specific symptoms not 
fulfilling the diagnosis of CHF,6 namely palpitations (n=80; 
35%), atypical chest pain (n=55; 24%), and presyncope/syn-
cope (n=16; 7%). Importantly, none was symptomatic for 
undue dyspnea or asthenia on ordinary physical activity or 
was receiving loop diuretic at study entry. The remaining 77 
patients were completely asymptomatic and underwent clini-
cal investigation because of family history of NICM (n=39; 
17%), history of hypertension-associated left bundle branch 
block (n=31; 14%), and anthracycline exposure (n=7; 3%). 
Significant coronary artery disease was excluded by means of 
invasive coronary angiography in 203 patients and of cardiac 
computed tomography in the remaining 25 patients. Sixty-one 
(27%) patients showed LGE, and the median extent of LGE 
was 3 segments (range, 1–10). Baseline characteristics in the 
overall study population and in patients with and without LGE 
are reported in Table 1. Baseline characteristics were well bal-
anced in the 2 groups, with the exception of LV mass index 
that tended to be higher in patients with LGE (P=0.061).
Clinical Follow-Up
The median follow-up duration was 23 months (13–37 
months). During follow-up, we identified 49 events.  Thirty-one 
of 61 patients with LGE reached the combined end point when 
compared with 18 of 167 (11%) patients without LGE (haz-
ard ratio, 5.10 [2.78–9.36]; P<0.001; Figure 2; Table 2). All 
cardiac deaths were because of CHF and occurred at a similar 
rate in patients with and without LGE. However, patients with 
LGE had a greater risk of developing CHF when compared 
with patients without LGE (hazard ratio, 5.23 [2.61–10.50]; 
P<0.001; Figure 3; Table 2). During follow-up, 16 patients 
(7%) underwent device implantation, of which 11 received an 
ICD combined with cardiac resynchronization therapy and 5 
received an ICD alone. Six patients implanted the device after 
the onset of CHF. Among the remaining 10 patients, 9 had 
severe LVSD (ejection fraction, <35%), despite treatment with 
optimal medical therapy for ≥12 months and arrhythmic bur-
den documented at 24-hour Holter monitoring or ECG moni-
toring (8 patients had >1 episode of nonsustained ventricular 
tachycardia and 1 patient had an episode of sustained ventric-
ular tachycardia), and 1 patient had moderate LVSD (ejection 
fraction, 43%) and an episode of sustained ventricular tachy-
cardia documented at 24-hour Holter monitoring. During 
follow-up, patients with LGE had higher rate of aborted SCD 
when compared with patients without LGE (hazard ratio, 8.31 
[1.66–41.55]; P=0.010; Table 2). All cases of aborted SCD 
(n=8) were because of appropriate ICD intervention.
Predictors of Clinical Outcomes at Univariate and 
Multivariate Analyses
At univariate analysis, the presence and extent of LGE predicted 
the combined primary end point. Advanced age, longer history 
of cardiomyopathy, higher LV volumes and mass, and lower LV 
ejection fraction were the other covariates associated with the 
occurrence of combined end point during follow-up (Table 3). 
However, at multivariate analysis, only the presence and extent of 
LGE and age remained independent predictors of the combined 
end point (model 1a and 1b; Table 4). These results were con-
firmed when LV end-systolic volume index replaced LV ejection 
fraction in the multivariate models (model 2a and 2b; Table 4).
Incremental Value of LGE for Prediction  
Clinical Outcomes
Information on the presence and extent of LGE made a size-
able difference in the prediction of combined end point. In 
particular, the addition of parameters of LV remodeling and 
function (ie, LV volumes, mass, and ejection fraction) to the 
model, including only clinical data (age and duration of car-
diomyopathy), did not yield any improvement in the predic-
tion of outcome. However, the addition of information on the 
presence or extent of LGE to the multivariate models yielded 
a significant improvement in outcome prediction (Figure 4).
Risk Reclassification
For the composite end point, the addition of LGE status to 
the model based on age and LV ejection fraction resulted in 
an overall correct reclassification of 29.6% (95 confidence 
interval, 17.4%–41.7%; P<0.001). Among 179 patients who 
did not experience the composite end point, 37 patients were 
correctly reclassified in the low-risk group, whereas 6 patients 
were incorrectly upgraded in the high-risk group (Table 5). 
Among the 49 patients who had the composite end point during 
follow-up, 6 patients were correctly reclassified in the high-
risk category. For the onset of CHF, the addition of LGE status 
to the model based on age and LV ejection fraction yielded 
an overall correct reclassification of 25.4% (95% confidence 
Figure 2. Kaplan–Meier curves for composite end point. LGE 
indicates late gadolinium enhancement.
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interval, 11.5%–39.2%; P<0.001). Among 191 patients who 
did not develop CHF during follow-up, 41 patients were cor-
rectly reclassified in the low-risk group, whereas 8 patients 
were incorrectly reclassified in the  high-risk category. Among 
the 37 patients who experienced CHF, 4 patients were cor-
rectly reclassified in the high-risk category and 1 patient was 
incorrectly downgraded in the low-risk group (Table 6).
Discussion
We found that in patients with NICM without history of 
CHF, the presence and extent of LGE were associated with 
an increased likelihood of the composite end point, including 
cardiac death, development of CHF, and aborted SCD. These 
associations were independent of other important prognostic 
determinants, including age, duration of cardiomyopathy, and 
the degree of LV remodeling and dysfunction. Moreover, the 
addition of the presence or extent of LGE to models, including 
clinical data alone or in combination with parameters of LV 
remodeling and function, yielded a significant improvement in 
outcome prediction. Net reclassification improvement analy-
ses disclosed that the addition of LGE status to models based 
on age and LV ejection fraction resulted in a correct reclas-
sification of nearly one third of patients for the composite end 
point and the development of CHF.
Reactive (interstitial and perivascular) and replacement myo-
cardial fibrosis are hallmarks of NICM.21,22  Contrast-enhanced 
CMR with LGE technique is accurate for an in vivo detection 
and quantification of replacement fibrosis, a scarring process 
that occurs in response to myocytes necrosis.11,14 Studies by 
several groups underscored that LGE is an independent pre-
dictor of outcome in patients with NICM and history of CHF 
based on a composite of cardiovascular death, CHF hospital-
ization, or appropriate ICD interventions.3,11–14 Recently, in a 
cohort of 472 consecutive patients with NICM, Gulati et al14 
demonstrated that the presence and extent of LGE provided 
an independent prognostic information for all cause of mortal-
ity and SCD. However, more than half of patients complained 
with symptoms of CHF at study entry, and the proportion of 
asymptomatic patients at enrollment but with antecedent epi-
sodes of CHF was not specified. The present study expands 
Table 2. Outcome Data
Outcome Overall (n=228) Patients With LGE (n=61)
Patients Without 
LGE (n=167) Hazard Ratio (95% CI) P Value
Combined end point, n (%) 49 (21) 31 (51) 18 (11) 5.104 (2.783–9.361) <0.001
  Cardiovascular deaths 4 (2) 1 (2) 3 (2) 1.241 (0.110–13.941) 0.861
  CHF 37 (16) 24 (39) 13 (8) 5.234 (2.609–10.500) <0.001
  Aborted SCD 8 (4) 6 (10) 2 (1) 8.314 (1.664–41.548) 0.010
Hazard ratio is calculated for patients with LGE vs those without LGE. P values are obtained from univariate Cox proportional hazard models. CHF indicates congestive 
heart failure; CI, confidence interval; LGE, late gadolinium enhancement; and SCD, sudden cardiac death.
Figure 3. Kaplan–Meier curves for the development of conges-
tive heart failure. LGE indicates late gadolinium enhancement.
Table 3.  Univariate Cox Proportional Hazards Analysis for 
Composite End Point
Variables at Baseline HR (95% CI) P Value
Age, y 1.040 (1.018–1.062) <0.001
Sex (women) 0.669 (0.321–1.396) 0.284
BMI, kg/m2 1.051 (0.997–1.131) 0.184
Family history of CM 0.935 (0.505–1.876) 0.935
Diabetes mellitus 1.031 (0.367–2.896) 0.953
Hypertension 0.893 (0.464–1.719) 0.735
Dyslipidemia 0.966 (0.522–1.788) 0.913
Smoking 1.392 (0.785–2.467) 0.258
Alcohol abuse 0.907 (0.219–3.764) 0.893
Duration of CM, mo 1.007 (1.003–1.012) 0.002
Hemoglobin, g/dL 1.046 (0.798–1.371) 0.744
Creatinine, mg/dL 1.251 (0.262–5.969) 0.779
Atrial fibrillation 1.391 (0.492–3.932) 0.533
Presence of LBBB 1.243 (0.672-2.2.300) 0.489
QRS duration, ms 1.007 (0.993–1.021) 0.322
Presence of LGE 5.104 (2.783–9.361) <0.001
LGE extent (no. of segment) 1.168 (1.069–1.277) 0.001
LVEDVi, mL/m2 1.008 (1.000–1.016) 0.044
LVESVi, mL/m2 1.009 (1.002–1.017) 0.013
LVSVi, mL/m2 0.987 (0.959–1.015) 0.369
LVMi, g/m2 1.018 (1.006–1.030) 0.004
LVEF, % 0.962 (0.934–0.990) 0.009
BMI indicates body mass index; CI, confidence interval; CM, cardiomyopathy; 
EDVi, end-diastolic volume index; EF, ejection fraction; ESVi, end-systolic volume 
index; HR, hazard ratio; LBBB, left bundle branch block; LGE, late gadolinium 
enhancement; LV, left ventricular; Mi, mass index; and SVi, stroke volume index.
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the current knowledge about the clinical significance of fibro-
sis in the risk stratification of patients with NICM by reporting 
the strong and independent prognostic value of LGE in NICM 
subjects without history of CHF.
Most of the information on preclinical LVSD derives from 
large epidemiological cohort studies, showing that this condi-
tion is as common as CHF in the general population and is 
predominantly associated with ischemic heart disease.6,8,9 In 
a community-based cross-sectional cohort study, Wang et al6 
reported that subjects with preclinical LVSD had increased risk 
of developing CHF and death when compared with those with 
normal LV systolic function irrespective of baseline cardiovas-
cular risk factors and the cause of ventricular dysfunction. To 
the best of our knowledge, our study is the first to show that 
in patients with NICM without history of CHF, the presence 
of LGE at baseline CMR conferred a 5-fold increased risk of 
experiencing the composite end point, and the strong prognos-
tic predictive value of LGE was independent of other important 
prognostic determinants, including age, duration of cardiomy-
opathy, LV volumes, mass, and ejection fraction. Myocardial 
LGE was also an independent prognostic predictor when semi-
quantitatively graded as number of LV segments with LGE, 
indicating that not only the presence but also the burden of 
fibrosis is an important determinant of outcome. Of note, most 
of the events were related to the development of CHF during 
follow-up, suggesting that baseline LGE detection is capable 
to predict the transition from preclinical to symptomatic stage. 
Fibrosis has been regarded as a marker of disease severity, 
reflecting the burden of initial myocardial damage and subse-
quent injury because of adverse LV remodeling.23 However, 
there are cumulating evidences supporting the knowledge that 
fibrosis is not a fixed marker of disease severity24 but rather a 
dynamic process that may play a causative role in the progres-
sion of LVSD and ensuing onset of CHF.25
Currently, risk stratification in patients with preclinical 
LVSD is primarily based on the degree of LVSD in the view 
of the fact that the likelihood of CHF and death augments with 
increasing the degrees of LVSD.6 In patients with NICM and 
CHF, LV ejection fraction is a validated independent prognos-
tic predictor26,27 even though the relationship between LV sys-
tolic function and outcome is not linear and becomes weaker 
in patients with severe LVSD.1,28 Risk stratification based on 
LV ejection fraction is also limited by the fact that more than 
one third of patients with NICM experiences a consistent and 
sustained improvement of LV ejection fraction after optimiza-
tion of medical therapy irrespective of the severity of initial 
LV dilatation and dysfunction.24,29 Thus, effective risk strati-
fication remains challenging in NICM particularly in subjects 
without history of CHF also because of the paucity of the data 
in this specific subgroup of patients. A remarkable finding of 
our study is that the addition of presence or extent of LGE to 
clinical data alone or in combination with parameters of LV 
remodeling and function significantly improved the outcome 
prediction. Furthermore, net reclassification improvement 
analyses showed that the addition of LGE status to models 
based on age and LV ejection fraction yielded an improvement 
of risk stratification for both composite end point and onset 
of CHF. For example, in patients who did not experience the 
composite end point, the use of LGE status correctly reclassi-
fied in low-risk group as many as 56% of patients incorrectly 
allocated to high-risk category by the model based on age and 
LV ejection fraction. Similarly, in patients who had the com-
posite end point during follow-up, the addition of LGE status 
to the model, including age and LV ejection fraction, correctly 
reclassified 24% in the high-risk group. Overall, these findings 
suggest that LGE improves the prediction of outcome and risk 
stratification in patients with NICM without history of CHF.
Current guidelines recommend ICD implantation for pri-
mary prevention of SCD in patients with NICM, symptoms 
of CHF, and LV ejection fraction <35%, despite ≥3 months of 
treatment with optimal pharmacological therapy.30 In the pres-
ent study, 16 patients (7%) underwent ICD implantation alone 
or in combination with cardiac resynchronization therapy. Six 
patients with severe LVSD received device after the onset of 
CHF; whereas among the remaining 10 patients, 9 had severe 
LVSD not responding to optimized medical therapy and docu-
mented ventricular arrhythmic burden and 1 patient had moder-
ate LVSD and an episode of sustained ventricular tachycardia. 
Patients with LGE had an 8-fold increased risk of appropriate 
ICD intervention when compared with those without LGE.
The validity of this result is limited by the few cases 
of aborted SCD. Nonetheless, this can be regarded as a 
Table 4. Multivariate Cox Proportional Hazards Analysis for Composite End Point
Variables at 
Baseline
Model 1 Model 2
Model 1a Model 1b Model 2a Model 2b
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Age, y 1.038 (1.013–1.063) 0.003 1.049 (1.021–1.078) 0.001 1.036 (1.011–1.062) 0.004 1.049 (1.020–1.078) 0.001
Duration of CM, mo 1.004 (0.998–1.009) 0.175 1.003 (0.998–1.009) 0.282 1.004 (0.998–1.009) 0.162 1.003 (0.998–1.009) 0.278
Presence of LGE 4.020 (2.082–7.762) <0.001 N/A N/A 4.152 (2.142–8.048) <0.001 N/A N/A
LGE extent  
(no. of segment)
N/A N/A 1.239 (1.111–1.382) <0.001 N/A N/A 1.241 (1.114–1.383) <0.001
LVEDVi, mL/m2 1.006 (0.993–1.019) 0.378 1.007 (0.994–1.020) 0.318 0.991 (0.959–1.025) 0.603 0.999 (0.966–1.034) 0.974
LVESVi, mL/m2 N/A N/A N/A N/A 1.020 (0.986–1.056) 0.250 1.010 (0.975–1.046) 0.578
LVMi, g/m2 0.998 (0.982–1.013) 0.770 0.999 (0.983–1.015) 0.884 0.998 (0.983–1.014) 0.828 0.999 (0.983–1.015) 0.912
LVEF, % 0.997 (0.934–1.021) 0.305 0.989 (0.944–1.035) 0.625 N/A N/A N/A N/A
CI indicates confidence interval; CM, cardiomyopathy; EDVi, end-diastolic volume index; EF, ejection fraction; ESVi, end-systolic volume index; HR, hazard ratio; LGE, 
late gadolinium enhancement; LV, left ventricular; Mi, mass index; and N/A, not applicable.
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 hypothesis-generating finding, warranting further investigations 
to assess the value of LGE in predicting SCD in patients with 
NICM without history of CHF. Of note, in patients with NICM 
and CHF, there are cumulating evidences, suggesting that fibro-
sis may be a useful marker for risk stratification of SCD.12,14,31 
Although the mechanisms of SCD in NICM are not yet com-
pletely understood, recent evidences suggest that fibrosis serves 
as anatomic substrate for reentry ventricular arrhythmias.31,32
Limitations
This is a multicenter study performed in 3 tertiary referral 
centers by adopting a prespecified standardized protocol for 
both clinical and CMR approaches and a centralized analysis 
of data. Referral bias might be a limitation of the study. The 
retrospective assignment of CHF could have led to misclas-
sification. However, this potential limitation was minimized 
by the prospective and standardized collection of the data. 
The study comprised a limited number of subjects followed 
up for a median of 2 years who were mainly enrolled at center 
A. Larger studies with long-term follow-up are warranted to 
address the prognostic value of fibrosis fully in this subset of 
patients with NICM with particular respect to survival. With 
respect to CMR examination, the choice of contrast agent was 
left to each center’s discretion. Although there are differences 
in contrast agent relaxivity, this aspect unlikely interfered 
with the visual discrimination and semiquantitative analysis 
Figure 4. Multivariate analyses showing the incremental value of late gadolinium enhancement (LGE) in predicting outcome when com-
pared with models, including clinical data alone (age and duration of cardiomyopathy) or in combination with cardiovascular magnetic 
resonance (CMR) parameters of left ventricular (LV) remodeling and function (LV volumes, mass, and ejection fraction). AIC indicates 
Akaike Information Criterion; BIC, Bayesian Information Criterion; and LL, log likelihood. *P<0.001; †P>0.050.
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of LGE. The latter was based on an easily obtainable semi-
quantitative grading based on several LV segments showing 
LGE. This approach was preferred to (semi)automatic quan-
tification of LGE using signal intensity threshold because it 
reflects more closely what is routinely done in clinical prac-
tice. The definition of preclinical LVSD was based on reduced 
LV ejection fraction, detected at transthoracic echocardiog-
raphy and confirmed by CMR, in the absence of history of 
CHF as defined by well-established diagnostic criteria.6,33 
However, the functional status was not evaluated by objective 
testing or a structured interview. Only 16 patients underwent 
ICD implantation and 8 of them received an appropriate ICD 
intervention during follow-up, a finding consistent with a par-
ticularly high risk of aborted SCD. Four of 8 patients with an 
appropriate ICD intervention had positive familial history for 
NICM, but we did not perform genetic counseling or testing. 
Thus, it cannot be excluded that some patients bore a sporadic 
or familiar mutation of genes associated with NICM pheno-
type and high risk of SCD.34 Given the absence of established 
thresholds for defining the risk of composite end point and 
the development of CHF, in net reclassification improvement 
analyses, the choice of risk categories was based on the cur-
rent study data. The adoption of different cutoff values might 
have yielded diverse results. Anyway, we performed multiple 
analyses (data not shown) using different categories of risk, 
and results remained consistent in all net reclassification 
improvement analyses. Furthermore, LGE technique allows 
the detection and quantification of replacement fibrosis. The 
quantification of interstitial fibrosis by T1 mapping may be of 
value in this setting.35
Conclusions
Myocardial fibrosis is a strong and independent predictor of 
adverse outcome in patients with NICM without history of 
CHF, providing incremental prognostic information and sig-
nificant improvement on risk stratification beyond clinical 
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CLINICAL PERSPECTIVE
Non–ischemic cardiomyopathy (NICM) is a major cause of congestive heart failure (CHF) with 5-year mortality high as 20%. 
A preclinical phase may precede the development of CHF in patients with NICM. However, information on this condition is 
scarce, given that most of the data are focused on preclinical left ventricular dysfunction because of ischemic heart disease. In this 
multicenter longitudinal prospective study, we have investigated the prognostic significance of myocardial fibrosis detected by 
late gadolinium enhancement technique using contrast-enhanced cardiovascular magnetic resonance in a cohort of patients with 
NICM without history of CHF. Among 765 patients with NICM studied with cardiovascular magnetic resonance, 228 patients 
without history of CHF were enrolled in the study and prospectively followed up (median, 23 months) for the composite end 
point of cardiac death, onset of CHF, and aborted sudden cardiac death. Myocardial fibrosis was detected in 61 (27%) patients. 
Thirty-one of 61 (51%) patients with fibrosis reached combined end point when compared with 18 of 167 (11%) patients without 
fibrosis (hazard ratio, 5.10 [2.78–9.36]; P<0.001). Multivariable analysis showed that fibrosis was associated with high likeli-
hood of composite end point independent of other prognostic determinants, including age; duration of cardiomyopathy; and left 
ventricular volumes, mass, and ejection fraction (hazard ratio, 4.02 [2.08–7.76]; P<0.001). Moreover, addition of LGE to age and 
left ventricular ejection fraction improved risk stratification for composite end point (net reclassification improvement, 29.6%) 
and onset of CHF (net reclassification improvement, 25.4%; both P<0.001). We have shown that in patients with NICM without 
history of CHF myocardial fibrosis is a strong and independent predictor of outcome, providing incremental prognostic informa-
tion and improvement in risk stratification beyond clinical data and degree of left ventricular dysfunction.
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SUPPLEMENTAL MATERIAL 
 Supplemental Methods 
Parameters of CMR sequences used by diverse 1.5 T scanners in the 3 Centers. 
____________________________________________________________________________________________________________________ 
     Cine b-steady state free precession   T1-weighted fast gradient-echo  
            Inversion-recovery  
____________________________________________________________________________________________________________________ 
Discovery MR, GE  FOV: 380-400 mm; TR/ TE: 3.2/1.4ms;    FOV: 380-400 mm; TR/TE: 6.7/1.6ms 
    α: 50°; matrix: 256x224; ST: 8 mm;    α: 20°, matrix: 256x192, ST:8mm;  
    no interslice gap      no interslice gap        
    
       
Intera CV, Philips  FOV: 350-400 mm; TR/ TE: 3.6/1.8 ms;    FOV: 350-400 mm; TR/TE: 4.5/1.3ms 
    α: 60°; matrix: 256x160; ST: 8 mm;    α: 15°, matrix: 256x128, ST:5mm;  
    no interslice gap      no interslice gap;          
 
CVi, GE   FOV: 350-400 mm, TR/TE: 3.2/1.6 ms,   FOV: 380-420 mm; TR/TE: 4.6/1.3ms  
    α: 60°, matrix: 256x256, ST: 8 mm;     α: 20°; matrix: 256x192; ST: 8 mm; 
    no interslice gap      no interslice gap 
            ST: 8 mm; no interslice gap 
_______________________________________________________________________________________________________________________________ 
Table Legend: α : flip angle;  FOV: field of view; ST: slice thickness; TE: echo time; TR: repetition time. 
